Background Immune checkpoint inhibitor (ICI) monoclonal antibodies (mAbs) targeting
cytotoxic T-lymphocyte antigen 4 (CTLA-4), programmed cell death protein 1 (PD-1) or its
ligand (PD-L1) produce unique toxicity profiles. The objective of this review was to identify
patterns and incidence of immune-related adverse events (irAE) based on tumour type and
ICI class. Methods Medline, EMBASE and COCHRANE databases were searched to identify
prospective monotherapy trials of ICIs from 2003 to November 2015. Paired reviewers …

Abstract Tumour-and Class-Specific Patterns of Immune-related Adverse Events of Immune
Checkpoint Inhibitors: A Systematic Review. In this systematic review, two pairs of reviewers
searched MEDLINE, Embase, and Cochrane databases for prospective trials of solid tumors
with single-agent treatment arms including ICIs. Interestingly, multivariate analysis
demonstrated that although PD1/PD-L1 inhibitor use was a risk factor for pneumonitis, tumor
type was not.